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ABSTRACT
Frequent genetic alterations discovered in FGFRs and evidence implicating some 
as drivers in diverse tumors has been accompanied by rapid progress in targeting 
FGFRs for anticancer treatments. Wider assessment of the impact of genetic changes 
on the activation state and drug responses is needed to better link the genomic 
data and treatment options. We here apply a direct comparative and comprehensive 
analysis of FGFR3 kinase domain variants representing the diversity of point-
mutations reported in this domain. We reinforce the importance of N540K and 
K650E and establish that not all highly activating mutations (for example R669G) 
occur at high-frequency and conversely, that some “hotspots” may not be linked to 
activation. Further structural characterization consolidates a mechanistic view of FGFR 
kinase activation and extends insights into drug binding. Importantly, using several 
inhibitors of particular clinical interest (AZD4547, BGJ-398, TKI258, JNJ42756493 and 
AP24534), we find that some activating mutations (including different replacements 
of the same residue) result in distinct changes in their efficacy. Considering that 
there is no approved inhibitor for anticancer treatments based on FGFR-targeting, 
this information will be immediately translatable to ongoing clinical trials.
INTRODUCTION
Fibroblast growth factors (FGFs) and their receptors 
(FGFR1-4) regulate a wide range of physiological processes 
including embryogenesis, wound healing, inflammation 
and angiogenesis as well as adult tissue homeostasis [1, 
2]. Importantly, aberrant FGF/FGFR signaling has been 
linked to several developmental syndromes and a broad 
range of human malignancies [3, 4]. The involvement in the 
pathology of many cancer types provides a strong rationale 
for development of effective agents for these targets; 
consequently, there is a large ongoing effort to develop 
FGFR inhibitors as anticancer treatments [5, 6].
Recent applications of deep sequencing technologies 
have resulted in the discovery of frequent alterations 
in FGFR molecules; the alterations include point-
mutations, overexpression and fusion genes [7–9]. Very 
recent analysis of about 5000 solid tumors provided a 
comprehensive picture of the FGFR alterations in cancer 
[10], generally consistent with the data combined from 
individual, smaller studies reported previously (examples 
include [11–17]). Based on these studies it is likely that 
FGFR aberrations occur in about 7% of solid tumors 
and almost every type of malignancy examined has been 
associated with FGFR aberrations; most commonly 
affected were urothelial, breast, endometrial, squamous 
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2lung cancers and ovarian cancer. The most frequently 
detected aberration appears to be gene amplification, 
in particular amplification of FGFR1, resulting in 
overexpression. Rearrangements resulting in fusion 
proteins (the most frequent being FGFR3TACC3-fusion) 
have been so far observed in smaller numbers compared to 
amplifications and mutations. Point-mutations have been 
detected in all FGFRs and are likely to represent about one 
third of all aberrations; they appear to be more frequent in 
FGFR3 and FGFR2 compared with FGFR1 and FGFR4.
The field of FGFR targeting has progressed 
rapidly in recent years especially owing to the further 
evaluation of nonselective and the development of novel 
FGFR-selective tyrosine kinase inhibitors (TKIs), many 
of which are currently in clinical trials [6]. The most 
clinically advanced compounds are nonselective TKIs 
(including ponatinib, brivanib, nintedanib, lenvatinib, 
dovitinib and lucitanib) that also have inhibitory activity 
against some other RTKs (such as VEGFRs). However, 
accumulative side effects and a modest efficacy of some 
of these compounds towards FGFRs have prompted the 
development of selective and highly potent FGFR TKIs, 
including AZD4547, BGJ-398 and JNJ42756493 [18–20]. 
It is also becoming apparent that optimal therapeutic 
application of FGFR inhibitors requires knowledge of the 
molecular profiles of populations that will benefit most 
from these drugs. Data providing information about the 
rates and types of FGFR aberrations in a variety of cancer 
types, as summarized above, will no doubt help to aid 
design of clinical trials.
The next rate-liming step to understand the clinical 
implications of such abundant genomic data, however, 
is the wider assessment of the causative role of these 
alterations found in cancer; the impact on protein function, 
including activation state and drug responses, needs to be 
assessed. In particular, point mutations occur in all regions 
of the receptor molecules including extracellular, trans-
membrane and kinase domains of FGFR1-4, suggesting 
diverse outcomes and mechanisms [7, 9]. Several pre-
clinical studies focusing on some of the frequently 
observed mutations demonstrated their oncogenic 
potential. For example, FGFR3 extracellular S249C 
substitution that occurs in more than 70% of urothelial 
tumors harboring mutations has been shown to enhance 
receptor phosphorylation, downstream signaling, saturation 
density in urothelial cells and to induce transformation 
of mouse fibroblasts [21]. Furthermore, viability and 
proliferation of some cancer cell lines with the FGFR3 
S249C substitution was compromised by FGFR inhibitors 
including the FGFR-specific AZD4547 compound [22]. 
Among FGFR kinase domain (KD) cancer mutations, 
another FGFR3 activating mutation, K650E, has been 
most extensively characterized [14, 21, 23]. However, 
to our knowledge, there is to date no comprehensive 
study in which different FGFR cancer variants have been 
directly compared and the impact of mutations assessed 
quantitatively. Furthermore, it is not clear how different 
primary or acquired mutations can affect responses to 
the emerging clinically promising inhibitors, including 
a number of nonselective and selective TKIs. Because 
all currently tested TKIs inhibit receptor kinase activity 
by interfering with the binding of ATP or substrates of 
the tyrosine kinase domain, mutations occurring within 
this domain are likely to be particularly relevant in this 
context. With these aims in mind, here we describe the 
effect of FGFR KD mutations on kinase activity, using 
a comprehensive panel, and distinct signatures of drug 
efficacy for different activating FGFR variants.
RESULTS
Reported mutations in FGFR KD
To obtain a comprehensive insight into mutations 
affecting the intracellular portion (and in particular KD) 
of FGFRs, we compiled missense mutation data and 
performed multiple sequence and structure-based analyses 
(Figure 1, Supplementary Table S1).
The intracellular portion (residues 397-806 for 
FGFR3) comprises the juxtamembrane region, KD and 
C-terminal regions. The number of observed mutations 
at each residue within the intracellular portion of FGFR3 
was compiled from several cancer databases (COSMIC, 
TCGA, ICGC and BioMuta) covering all cancer types 
(Figure 1A, top). Considering the high degree of similarity 
between FGFR1-4, the same analysis was also performed 
for all FGFRs and displayed using amino acid numbering 
for FGFR3 (Figure 1A, bottom). Two frequently mutated 
positions (“hotspots”) were identified in FGFR3 KD in 
cancer (K650 and G697) and a third (corresponding to 
N540 in FGFR3) was revealed only when considering 
all FGFRs (Figure 1A). The most frequent amino acid 
replacements at the position corresponding to FGFR3 
K650 were E and M while others such as N, Q and T were 
observed less frequently. For the position corresponding 
to FGFR3 N540, the most frequent mutation was to K 
compared to S, D or H. The frequent replacement G697C 
was reported only for FGFR3 (Figure 1A).
It has been previously highlighted that a number of 
cancer mutations, in particular in FGFR2 and FGFR3, have 
also been described in various developmental syndromes 
such as bone dysplasia [4]. Positions mutated in FGFR3 
in this type of dysplasia (Figure 1B top) included not only 
one of the hotspots observed in FGFR3 in cancer (K650) 
(Figure 1A top) but also the N540 hotspot position (Figure 1A 
bottom). N540 FGFR3 mutations in bone dysplasia reflect 
the overall picture of FGFR1-4 mutations in cancer with 
the replacement N540K being the most frequently observed 
[24](Figure 1B top). A distinct pattern of cancer mutations 
in FGFR1-4 can reflect differences in cancer types and their 
etiology, with FGFR3 mutations being most prevalent in a 
single cancer type (i.e bladder cancer) [7–9].
3Figure 1: Point mutations in the intracellular region of FGFR. A. Positions of point mutations and number of observations across 
different cancer types reported for FGFR3 (top) and for all FGFRs (FGFR1-4) (bottom). Hot spot positions are highlighted in red and their 
specific substitutions and numbers (in brackets) shown in the insets. B. Positions of point mutations found in skeletal dysplasia reported for 
FGFR3 (top) and for all FGFRs (FGFR1-4) (bottom). Specific substitutions for positions N540 and K650 in FGFR3 are shown in the inset. 
Positions highlighted in red are those found in both, FGFR3 in different cancers and in FGFRs in skeletal dysplasia. C. Secondary structure 
elements of the FGFR3 KD. β-strands (1-12, β11 is not present) are shown as grey boxes and α-helices (C-J) as red boxes; the key loops 
or disordered regions are indicated in purple. D. 3D representations of an inactive (left) and active (right) FGFR3 KD based on previously 
reported crystal structures of FGFR1 (PDB: 4UWY and 3GQI) and high degree of conservation (see Supplementary Figure S1). Regions 
implicated in transition from an inactive to an active conformation are highlighted in different colors. Hot spot positions across different 
cancer types reported for FGFR3 (K650 and G697) are shown in red; one additional hot spot observed in analysis of cancer mutations in 
all FGFRs (N540) is shown in purple.
4Comparison of positions mutated in bone dysplasia 
in all FGFRs with those reported for FGFR3 in cancer 
(Figure 1B, bottom) highlighted common residues 
including I538, N540, K650 and R669. With respect to 
the secondary structure (Figure 1C), I538 and N540 are 
in the αC-β4 linker, K650 in the activation (A)-loop and 
R669 in αEF-β12 linker. The hot spot position G697 has 
not been observed in bone dysplasia in any of FGFRs and 
is present within the αF- αG linker.
A number of crystal structures of FGFR KD in 
non-phosphorylated and phosphorylated forms have 
been reported [25]. The 3D-structures highlighted the 
features that undergo substantial changes and play a key 
role in the activation process; of particular importance is 
the A-loop and so called “molecular brake” (Figure 1D, 
Supplementary Figure S1). When positions of FGFR3 
cancer mutations are highlighted in the FGFR KD 
structure, one hot spot (K650) and 9 other residues are 
present within the A-loop while R669 is in its vicinity. 
Residues N540 and I538 are part of the molecular brake.
In a broader context, linking genetic data with 
the functional outcome remains a challenge and the 
accuracy is such that most predictions should be seen 
as complementary to - rather than a replacement for - 
experimental evaluation [26, 27]. In addition to ranking 
based on observed mutation frequencies, there are 
a number of bioinformatics tools that can assess the 
possible impacts of a mutation (Supplementary Table S1A, 
Supplementary Figure S2). Many algorithms assume that 
mutations affecting protein function occur at evolutionarily 
conserved sites and the meta-predictor CONsensus 
DELeteriousness score (Condel) combines several of these 
[28]. More sophisticated predictors make use of available 
protein structures (such as SAAP, that predicts outcomes 
using multiple features, or 3D-clustering). Some structure-
based tools allow prediction of the energetic impacts of 
mutations; we used FOLDX [29] to predict changes in 
stability for all possible FGFR3 KD mutations and ranked 
them. Stability differences between active and inactive KD 
can predict mutations expected to shift equilibrium from 
inactive to active conformations.
We used these tools for analysis of all reported 
intracellular FGFR3 cancer mutations and also included 
some common mutations found in other FGFRs or in bone 
dysplasia. Based on this, we constructed a representative 
panel for experimental evaluation that covers different 
structural elements of the KD, frequencies, cancer types 
and different prediction outcomes (Table 1). The panel 
includes about 47% of all intracellular residues reported 
to be mutated in FGFR3 in cancer.
Kinase activity of FGFR3 KD variants
The number of cancer mutations in FGFR KDs that 
have been comprehensively assessed for their functional 
impact is limited, with the most emphasis being on 
replacements at positions corresponding to FGFR3 K650 
and mutation corresponding to FGFR3 N540K [14, 21, 
23, 30, 31]. Some comparisons of mutations found in 
the context of bone dysplasia have also been reported 
[32–34]. However, very few studies compared a panel of 
cancer mutations or directly and quantitatively measured 
kinase activity; no such studies have been applied to 
FGFR3 KD.
Isolated FGFR KDs undergo auto-phosphorylation 
on several tyrosine residues and this property correlates 
well with the kinase activity towards natural and 
synthetic substrates. We used purified proteins of 26 
FGFR3 KD variants to directly compare the impact of 
different mutations on FGFR3 KD auto-phosphorylation 
(Figure 2A). The most frequent mutations at the hotspot 
positions, K650E and N540K, resulted in a large increase 
(up to 45-fold) in auto-phosphorylation. Interestingly, at 
both positions, the mutations observed less frequently, 
K650N and N540S, were also less activating. However, 
surprisingly, the most activating mutation in this assay 
was a non-hotspot mutation R669G. Another replacement 
at this position, R669Q, also resulted in an increase 
of auto-phosphorylation. The least activating among 
variants that increased FGFR3 KD auto-phosphorylation 
more than 7-fold was the I538V mutation. Results from 
further analysis of these activating variants in a substrate 
phosphorylation assay (Figure 2B, top panel) were 
generally consistent with the auto-phosphorylation data 
(Figure 2A).
Several other mutations, including V555M, 
D641G and D641N resulted in an increase of auto-
phosphorylation up to 7-fold (Figure 2A) and a similar 
increase in substrate phosphorylation (Figure 2B, middle 
panel). The V555M mutation, unlike other mutations 
in this panel, is an acquired resistance mutation to an 
FGFR inhibitor (AZ12908010) where the gatekeeper 
residue, V555, is replaced by a larger side-chain residue 
[22]. Gatekeeper mutations have been described in many 
kinases and several studies have shown an associated 
increase in kinase activity [35–37].
Twelve out of 26 analyzed mutations had very little 
or no effect on FGFR3 KD activity (Figure 2A and 2B, 
bottom panel). The number of observations in cancer 
for most of these mutations is low with the exception of 
G697C that represents one of the hotspots (Figure 1A).
Two mutations, D617G and G637W, completely 
abolished kinase activity (Figure 2A and 2B, bottom 
panel). Both residues are strongly conserved among 
protein kinases and some of the replacements of these 
residues in various kinases have been tested and shown 
to result in inactivation [38, 39]. D617 is the key catalytic 
residue and part of the HRD motif in the C-loop, while 
G637 resides in the A-loop as a part of the DFG motif. The 
DFG motif is surprisingly frequently mutated in the cancer 
kinome [38]. However, a G to W replacement has not been 
observed and tested previously and, as shown in Figure 2B 
5Table 1: Panel of FGFR3 variants selected for experimental studies
Substitution in 
FGFR3
Cancer
Primary tissue
Corresponding 
substitution in FGFR1, 
2 or 4 in cancer
Corresponding 
substitution in FGFRs 
in dysplasia
Summary of prediction of 
impact based on Condel (C) 
and FOLDX (F)***
E466K CNS ✓ FGFR2 - Deleterious (C)
A500T Pancreas - - Neutral to stabilizing for the 
active form (F)
I538F Hematopoietic - - Very destabilizing for the 
inactive form and neutral to 
destabilizing for the active form 
(F)
I538V - ✓ FGFR2 ✓ FGFR3, FGFR2 Neutral (F)
N540K - ✓ FGFR1, FGFR2, 
FGFR4
✓ FGFR3 Neutral to very stabilizing for the 
active form (F)
N540S Urinary tract ✓ FGFR1 ✓ FGFR3 Neutral (F)
V555M Hematopoietic - - Stabilizing for the active form 
(F)
P572A CNS - - Neutral (F)
C582F Ovary - - Neutral (F)
D617G Aerodigestive tract - - Deleterious (C)
Neutral to stabilizing for the 
active form (F)
E627D Urinary tract - - Neutral (F)
V630M Aerodigestive tract - - Neutral (F)
G637W Kidney - - Deleterious (C) Destabilizing for 
the inactive form and stabilizing 
to very stabilizing for the active 
form (F)
D641G Large Intestine - - Neutral (F)
D641N Urinary tract ✓ FGFR1 - Neutral (F)
H643D Urinary tract - - Neutral (F)
D646Y Urinary tract - - Neutral (F)
Y647C Lung** - - Neutral (F)
K650E Range of cancer types ✓ FGFR1, FGFR2, 
FGFR4
✓ FGFR3 Very stabilizing for the active 
form (F)
K650N Urinary tract Large 
Intestine
✓ FGFR2 ✓ FGFR3, FGFR2 Stabilizing for the active form 
(F)
N653H Urinary tract - Neutral (F)
R669G - ✓ FGFR2 ✓ FGFR3, FGFR2 Neutral to very stabilizing for the 
active form (F)
R669Q Large Intestine ✓ FGFR1 - Neutral to stabilizing for the 
active form (F)
V677I Large Intestine - - Neutral (F)
G697C Aerodigestive tract - - Neutral (F)
*red indicates hot spot positions in FGFR3 KD, purple indicates an additional hotspot position seen for FGFR1-4 KD
**mutation has been observed in a model of resistance to EGFR inhibitors
***FOLDX analysis for the panel was extended compared to analysis in Supplementary Table S1 to include additional 
structural information
6Figure 2: Kinase activity of selected FGFR3 variants harboring point mutations. A. Auto-phosphorylation of purified 
proteins incorporating region 455-768 of FGFR3 without (WT) and with indicated substitutions. Activity of each variant is expressed as a 
fold change compared to the WT (WT=1). B. FGFR3 proteins described in A were analyzed for substrate (poly Glu-Tyr) phosphorylation. 
Activities of highly activating variants (top) and activating variants (middle) are shown as a function of increasing FGFR3 concentrations; 
the activity of other variants (bottom) is expressed as a fold change compared to the WT. C. Comparison of non-phosphorylated (WT), 
phosphorylated (pWT) and K650E FGFR3 proteins in a substrate phosphorylation assay.
7(bottom panel), also results in kinase inactivation. In 
general, the importance of these inactivating mutations 
for cancer development remains unclear and specifically 
for FGFRs it could be linked to their suggested, context-
dependent tumour protective functions [40].
From these direct measurements of kinase activity 
it seems that a considerable number of mutations reported 
so far result in kinase activation to some degree and 
that replacements that cause activation are not limited 
to hotspot positions (Figures 2A and 2B). However, 
the comparison of a highly activating K650E and 
phosphorylated WT FGFR3 KD suggests that even these 
mutations do not fully convert mutated molecules to their 
active conformations (Figure 2C).
It could be expected that some mutations that map to 
the KD do not affect kinase activity directly as measured 
under conditions in vitro. In particular, the hotspot G697C 
mutation which does not have an effect in such assays 
(Figure 2A and 2B, bottom panel) could impact on 
FGFR3 function in a way that can only be detected in a 
cellular setting. To test this possibility, a stably transfected 
FGFR3 G697C NIH3T3 cell line was compared with 
cell lines expressing two other hotspot variants, K650E 
and N540K, and the WT FGFR3 cell line (Figure 3). In 
contrast to cell lines expressing FGFR3 K650E and N540K 
mutations, FGFR3 G697C NIH3T3 cell line did not 
show a transformed phenotype (Figure 3A) or anchorage 
independent growth (Figure 3B); there was no detectable 
increase in downstream phosphorylation events and levels 
of phospho-FGFR were comparable to the WT (Figure 3C).
Analysis of the FGFR3 R669G NIH3T3 cell line 
has shown that despite low expression levels, downstream 
signaling appeared to be enhanced as well as FGFR3 
phosphorylation (Figure 4A).
Comparison of our experimental data (Figure 2) 
with the assessments obtained using bioinformatics 
tools (Supplementary Table S1B and S1C) suggests 
that considering multiple methods together can 
provide insight into the influences of many panel 
mutations. Condel predicts three pathogenic mutations 
(E466K, D617G and G637W) that either reduce 
protein production or completely inactivate the kinase. 
Stabilization of active kinase is indicated by FOLDX 
with good specificity, but low sensitivity. However, most 
highly activating or moderately activating mutations 
have supporting evidence from either FOLDX or 
clustering (Supplementary Table S1B, Supplementary 
Figure S2). In particular, although not a hotspot, R669 
is within an identified cluster of observed A-loop cancer 
mutations.
Activation mechanism of FGFR3 R669G 
mutation
The residue corresponding to R669 in FGFR3 
is conserved and also mutated in all other FGFRs 
in cancer as well as in FGFR2 in bone dysplasia 
(Supplementary Table S1). To assess the mechanism 
that underpins activation, we first analyzed the R to 
G replacement in the context of FGFR1 KD that is 
more amenable to crystallography compared to FGFR3 
KD. As shown in Figure 4B, R675G FGFR1 KD 
variant also has higher activity compared to the WT. 
X-ray data collection and refinement statistics for the 
R675G FGFR1 KD 3D structure are summarized in 
Supplementary Table S2.
Comparison of this new FGFR1 R675G KD 
structure (Figure 4C, top) with inactive (apo) FGFR1 
KD (PDB: 4UWY) and active, FGFR1-3P (pdb 3GQI) 
(Figure 4C, bottom) structures shows that FGFR1 R675G 
KD differs from the inactive form and adopts a fold with 
great similarity to the active KD. Notably, in the inactive 
FGFR1 KD there is direct hydrogen bonding between 
R675 and H650 from the A-loop; in addition, R675 
is found to share a tight van der Waals interaction with 
active site tyrosine Y653 and H650 (Figure 4C, bottom 
left inset). These interactions are disturbed and broken in 
R675G mutant (Figure 4C, top inset), thus favoring the 
A-loop to adopt an open conformation as found in the 
active FGFR1-3P (Figure 4C, bottom right inset). In turn, 
this open conformation of the A-loop leads to several 
rearrangements of various control elements in the KD – 
including ordering of spine residues, dissociation in the 
molecular brake interacting residues, repositioning of the 
αC-helix and movement of the N-lobe toward the C-lobe.
To gain further insight into the activation mechanism 
of the R669G mutation in FGFR3, we performed NMR 
studies in which we compared the backbone amide 
chemical shift perturbations (CSPs) associated with the 
R669G mutation with those of the WT FGFR3 KD. Our 
results show that in addition to localized differences 
around the mutation, there are other differences in distant 
elements, consistent with a broader conformational change 
(Supplementary Figure S3). Of particular note are the 
significant CSPs in the αC-β4 loop and at the C-terminal 
end of the αC-helix, which likely report on the release of 
the molecular brake by the R669G mutation. The CSPs 
in helix αG and in the αF-αG linker also suggest altered 
interactions with the αEF helix and the activation loop, 
consistent with promotion of an active conformation.
Previous structural studies of FGFR2 KD 
highlighted a long-range allosteric communication linking 
the kinase hinge, the αC-helix and the A-loop [41]. It 
was also illustrated that some A-loop mutations (such as 
FGFR3 K650E), by forcing an active conformation of the 
loop, can change via this allosteric network the position of 
the αC-helix and also dissociate the molecular brake [23, 
41]. We suggest a similar allosteric mechanism for FGFR1 
R675G and corresponding FGFR3 R669G mutation that is 
in this case triggered by the loss of inhibitory interactions 
in the vicinity of the A-loop that involve the R675/669 
residue.
8Structural insights into drug binding
Several recent structural studies revealed binding 
pockets of some selective (BGJ-398 and AZD4547) and 
non-selective (TKI258 and AP24534) FGFR inhibitors 
in complexes with FGFR1 KD [37, 42, 43]. For the 
FGFR-selective inhibitor JNJ42756493 there is much less 
reported information despite its promise for clinical use 
[44]. To help rationalize functional differences between 
these compounds we generated the structure of FGFR1 
in complex with JNJ42756493 by soaking the compound 
into preformed crystals of FGFR1 KD in which there 
are two molecules of FGFR1 in the crystallographic 
asymmetric unit. The two monomers are highly similar, 
exhibiting rmsd values of 0.39 Å over 280 Å and 0.09 Å 
over 39 Å within 6 Å of the JNJ42756493 binding site. 
Figure 3: Analysis of G697C substitution in a cellular setting. Control NIH3T3 cells and NIH3T3 cells expressing FGFR3 WT, 
N540K, K650E or G697C variants were analyzed for: transformed phenotype (scale bar represents 200 μm) A. anchorage independent 
growth B. FGFR3 expression level (C. left top) and ERK phosphorylation status shown as pERK/ERK ratio (C. right). Following FGFR3 
immunoprecipation (with normalization for equal amounts) (FGFR3 IP), the phosphorylation status (pFGFR3) was subsequently assessed 
using anti-pY antibodies (C. left bottom). For the representative blots in panel C, lysates were prepared from cells subjected to serum 
withdrawal for 2 hrs in two separate experiments. See also Supplementary Figure S6.
9Further discussion will therefore refer to the structure of 
monomer A. The overall structure of FGFR1 KD bound to 
JNJ42756493 is shown in Figure 5A.
JNJ42756493 occupies the ATP-binding cleft of 
FGFR1 largely as expected on the basis of previous 
complexes between FGFR1 and other type-I inhibitors (e. 
g. BJG-398, AZD4547, PD173074 and TKI258) and where
the activation loop clearly exhibits a DFG-in conformation. 
The quinoxaline core of JNJ42756493 is observed to form a 
single hydrogen bond to the hinge region via the main chain 
amide of A564 while the dimethoxyphenyl ring is orientated 
perpendicular to the quinoxaline core and occupies the 
hydrophobic pocket located behind the gatekeeper residue 
(V561). One of the methoxy oxygen atoms is involved in 
a hydrogen bond with the backbone nitrogen atom of the 
DFG aspartate (D641). The methyl pyrazole solubilizing 
group extends away from the hinge region towards the 
solvent channel and does not make any specific interactions 
Figure 4: Impact of R669G substitution on function of FGFR3 in a cellular setting and on FGFR KD structure. 
A. NIH3T3 cells expressing FGFR3 WT or R669G variant were analyzed for FGFR3 expression level (left) and ERK phosphorylation 
status shown as pERK/ERK ratio (middle); following FGFR3 immunoprecipation (with normalization for equal amounts) (FGFR3 IP), 
the phosphorylation status (pFGFR3) was subsequently assessed using anti-pY antibodies (right). See also Supplementary Figure S6. B. 
Auto-phosphorylation of purified kinase domain proteins: FGFR3 WT, FGFR3 R669G, FGFR1 WT and FGFR1 with the corresponding 
substitution R675G. Activity of each variant is expressed as a fold change compared to the FGFR3 WT (WT=1). C. FGFR1 R675G (PDB: 
5FLF) (top), Apo FGFR1 (PDB: 4UWY) (bottom left) and FGFR1 3P-active (PDB: 3GQI) (bottom right) are represented as a cartoon 
diagram. The A-loop and αC helix are coloured in chocolate. The molecular break (MB) residues N546, E562 and K638 are represented as 
ball-and-stick model (green). The residues at the activation loop H650, I651, D652, Y653, Y654 and R/G 675 are shown as ball-and-stick-
model along with a surface around them. The R/G residues are coloured in blue while the nearby residues surrounding R675 are coloured 
in orange. The phospho-tyrosine (pY) residues in FGFR1 3P-active form are represented with their van der Waals surface as spheres.
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with the protein. A structural comparison of various drug 
compounds (JNJ42756493, BGJ-398, AZD4547, TKI258 
and AP24534; Supplementary Figure S4) bound to FGFR1 
KD clearly indicates that a unique feature of JNJ42756493 
is the amide side chain which extends into the region of the 
binding site normally occupied by the a-phosphate of ATP 
where it forms a hydrogen bond to the side chain of D641. 
In addition the terminal isopropyl group of this side chain 
also makes good van der Waals interactions with the protein 
in a shallow pocket formed by the side chains of N628, 
L630, A640 and D641 that has previously been referred 
to as the “pit” region [45]. Interestingly this indentation 
in FGFR1 has previously been found to be occupied 
by a methyl isoxazole moiety in a series of compounds 
containing a pyrazole core (PDB numbers: 4F64, 4F65, 
4NK9, 4NKA and 4NKS). The side chain modification 
to JNJ42756493 therefore likely makes a significant 
contribution to its overall binding strength and specificity. 
Considering that JNJ42756493, BGJ-398, AZD4547, 
TKI258 and AP24534 are all in clinical trials, structural 
comparison of their binding to FGFR KD (Supplementary 
Figure S4) will contribute to understanding their clinical 
differences.
Changes in drug efficacy due to activating 
mutations
It is well established that some acquired mutations 
in protein kinases greatly reduce drug binding; the best-
illustrated examples are gatekeeper mutations also 
described in FGFR3 (V555M) [22, 37]. The question 
of how primary mutations in FGFR KDs, in particular 
activating mutations, affect drug efficacy has not been 
addressed directly although studies of FGFR2 resistance 
mutations to TKI258 using BaF3 cells suggested this 
possibility [46]. However, with a number of FGFR 
inhibitors now in clinical trials it is important to establish 
accurately their comparative efficacies towards different 
FGFR variants.
We performed measurements of Ki for AZD4547, 
BGJ-398, TKI258, JNJ42756493 and AP24534 
using purified FGFR3 KD WT and variants R669G, 
K650E, N540S, N540K, V555M and I538V (Figure 
6, Supplementary Table S3). Ki values for the WT 
FGFR3 KD show the first direct comparison of these 
compounds (Figure 6A); several previous studies 
focused on a single drug [18, 19, 47]. JNJ42756493 is 
the most effective (Ki about 2 nM), closely followed 
by AZD4547 (Ki about 4.5 nM) while another FGFR-
specific inhibitor BGJ-398 has a Ki value similar to 
pan-kinase inhibitors TKI258 and AP24534 (within the 
range 65-95 nM) (Figure 6A, Supplementary Table S3). 
Mutations selected for this study include the gatekeeper 
(V555M) and several other activating mutations that 
are in the vicinity of the ATP binding pocket (N540S, 
N540K and I538V); R669G and K650E mutations are 
further away – however, they could have an allosteric 
effect (Figure 6B).
The impact of each mutation on drug binding is 
expressed as a fold-difference in Ki compared to the 
Figure 5: Structural insights into JNJ42756493 binding to FGFR1 KD. A. Cartoon representation of JNJ42756493 (in yellow) 
bound FGFR1 KD. The A-loop is colored in purple, P-loop in cyan and the hinge region in dark blue. A van der Waals surface area is shown 
around the drug JNJ42756493. B. Chemical structure representation of JNJ42756493. C. A close-up view of JNJ42756493 (in yellow) and 
surrounding residues shown as ball-and-stick model.
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Figure 6: Inhibitor efficacy for a subset of FGFR3 variants measured in vitro and in cells. A. Efficacy of indicated inhibitors 
on substrate phosphorylation by FGFR3 WT expressed as Ki values. B. A close-up view of FGFR1 KD structure in the complexes with an 
ATP-analogue, ACP (PDB: 3GQI). Residues corresponding to mutations in FGFR3 are highlighted and labeled using FGFR3 numbering. 
C. The effect of indicated substitutions on substrate phosphorylation by FGFR3 variants shown as difference in Ki compared to the wild 
type (WT=1). See Supplementary Table S3  for absolute values. D. Inhibitor efficacy in NIH3T3 stable cell lines. Efficacy of AZD4547 
(blue) and JNJ42756493 (black) towards: FGFR3 with the WT KD (FGFR3TACC3-fusion) (left) and N540K (middle) or K650E FGFR3 
(right) variants in NIH3T3 cells. Inhibitor concentrations used were 0, 50, 100, 500, 1000 and 2000 nM.
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FGFR3 KD WT (Figure 6C). Highly activating R669G 
and, in particular, hotspot mutation K650E had moderate 
effects on the efficacy of all inhibitors; all changes for 
K650E were within 4–fold (Figure 6C, Supplementary 
Table S3). In contrast, mutations at the hotspot position 
N540 had a more pronounced effect (up to 23-fold) and 
most affected the compounds with low Ki values, with 
the N540K substitution affecting AZD4547 more and 
N540S affecting JNJ42756493 more. As expected, the 
gatekeeper V555M mutation, conferring resistance to 
AZ12908010 (similar to AZD4547), had an impact on 
the efficacy of AZD4547 (about 20-fold). The change 
in efficacy of JNJ42756493 due to V555M mutation 
was even greater (about 200-fold) representing the 
biggest change observed in this panel. Interestingly, as 
we reported previously [37], the affinity of TKI258 for 
V555M was higher compared to the WT. Residue I538 
is in contact with N540 in the 3D structure [41] and the 
mutation I538V had substantial effect (up to 40-fold) on 
all inhibitors.
We further compared the effect of the two 
most potent FGFR-specific inhibitors AZD4547 and 
JNJ42756493 on hotspot mutations K650E and N540K 
in NIH3T3 cell lines. As previously reported [37] and 
shown in Supplementary Figure S5 NIH3T3 cells stably 
transfected with the “empty” expression vector are only 
marginally affected by FGFR inhibitors. An NIH3T3 
cell line expressing FGFR3TACC3-fusion protein 
was used for comparison with the K650E and N540K 
NIH3T3 cell lines because the FGFR3 KD in this fusion 
has the WT sequence and, furthermore, this cell line 
has similarly transformed phenotype (Figure 6D). For 
the WT KD, AZD4547 and JNJ42756493 cellular IC50s 
reflect the in vitro differences of about 2-3 fold (Figure 
6D, left and Supplementary Table S3). The K650E and 
N540K variants reduce efficacy of both compounds 
with the larger impact by the N540K mutation also 
showing a considerable difference between AZD4547 
and JNJ42756493 for this mutant (Figure 6D, middle 
and right).
Some of the differences between the effects of 
tested inhibitors on activating FGFR variants (Figure 6) 
are consistent with observations from structural 
studies. Based on the crystal structure of FGFR1 KD 
V561M, the interactions of the inhibitors within the 
ATP-binding pocket, and their chemical structures 
(Supplementary Figure S1), it is expected that the efficacy 
of the JNJ42756493 towards FGFR3 V555M would 
be particularly affected. Contributing factors include 
the higher rigidity of this compound, compared with 
AZD4547 and BGJ-398, and the nature of occupancy of 
the ATP-binding pocket resulting in higher affinity (Figure 
5, Supplementary Figure S1). In general, 3D structures 
alone are not sufficient to fully understand the mode and 
strength of drug binding [48] highlighting the importance 
of direct measurements performed here.
DISCUSSION
Many clinically relevant cancer mutations were 
identified based on recurrence rates. However, this 
strategy cannot be readily applied to alterations that occur 
in a minority of tumors or to situations where different, 
rare mutations create the same neoplastic phenotype via 
different mechanisms. In fact, some of these mutations 
are of functional significance and likely constitute drivers, 
therapeutic targets or mechanisms of therapy resistance 
[49]. Here we have applied a direct comparative analysis 
of FGFR KD variants that represent the diversity of all 
mutations found in cancer and characterized their impact 
on kinase activity; for a subset of activating mutations we 
have also established their responsiveness to several drugs 
of particular clinical interest.
Our data reinforce the importance of frequently 
observed mutations at positions corresponding to FGFR3 
N540 and K650 that occur in different FGFRs and in a 
range of cancer types as well as in bone dysplasia (Figures 
1–3, Supplementary Table S1) [7, 9, 24]. In particular, 
replacements N to K and K to E at the respective positions 
are highly activating in vitro and transforming in NIH3T3 
cells (Figures 2 and 3). In contrast, we have not been 
able to provide supporting evidence for an activating 
nature of FGFR3 mutation G697C (Figure 2 and 3). A 
relatively high number of observations of this mutation 
highlight FGFR3 G697C as another hotspot mutation 
(Figure 1). However, all observations of FGFR3 G697C 
were reported in a single study of oral squamous cell 
carcinomas (OSCC) [50]. It is possible that the activating 
potential of this mutation could be context dependent and 
involve interaction with another component(s) present in 
this type of epithelial cells. Interestingly, another study 
examining a comparable number of OSCC cases from 
a different population failed to detect FGFR3 G697C, 
arguing that this mutation is unlikely to be common 
even in this cancer type [51]. It is also conceivable that 
the occurrence of this mutation in a specific population 
could be unrelated to FGFR activation and involvement 
in OSCC. Further studies, focusing on FGFR3 G697C in 
epithelial cells rather than on comparative analysis shown 
here, would be needed to confirm this possibility.
A number of non-hotspot mutations have an 
impact on kinase activity, mainly resulting in moderate 
activation (Figure 2). At least some of these mutations 
are likely to have clinical relevance and they include a 
gatekeeper mutation (FGFR3 V555M) and a mutation 
(corresponding to FGFR3 I538V) also identified 
in a developmental disorder (hypochondroplasia) 
(Supplementary Table S1). The importance of mutations 
resulting in a lower degree of activation has been 
illustrated in developmental disorders, linking these 
mutations to less severe syndromes [52]; it is also 
possible that they could contribute to generation or 
progression of tumors or may be selected for after the 
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selective pressure of anti-FGFR treatments. Moreover, 
we have established that an infrequent cancer mutation 
corresponding to R669G in FGFR3, also found in bone 
dysplasia, greatly enhances kinase activity of FGFR 
(Figures 1 and 2). One observation that could be related 
to its low reported frequency in cancer is the finding of 
low expression levels of this mutation in transfected 
mammalian cells (compared to FGFR3 N540K, K650E 
or WT) (Figure 4) that might compromise its impact 
or could require additional changes in cancer cells 
to increase its stability or expression. Nevertheless, 
structural studies of this mutation in the context of 
FGFR1 KD (R675G) are fully consistent with its 
activating potential. Furthermore, we here reveal a 
new feature of FGFR KD that stabilizes the inactive 
conformation which, when disrupted by mutations, 
can result in activation – namely, a set of interactions 
in the vicinity of the A-loop that involve R669/675 
(Figure 4). Our new structural insights also consolidate 
observations resulting from structural studies of several 
other activating variants including FGFR2 N549H/T 
mutations in the molecular brake, FGFR2 K659N 
and FGFR3 K650E in the A-loop and FGFR1 V651M 
gatekeeper mutation affecting the regulatory spine [23, 
37, 41]. Although R669/675 and these other mutations 
affect different regions in FGFR KD, the local structural 
changes trigger alterations in FGFR KD allosteric 
networks resulting in a shift towards conformations 
resembling an active form of phosphorylated kinase.
Combined with several recent structural studies 
of inhibitory compounds bound to FGFR KDs [37, 42, 
43], our crystal structure of the JNJ42756493/FGFR1 
KD complex provides a detailed picture of common 
features and key differences in the extent and nature 
of their binding interactions (Figure 5, Supplementary 
Figure S4). While these structures provide an important 
basis for understanding and improving the function of 
FGFR inhibitors, there are also limitations, in particular 
understanding the consequence of specific FGFR 
mutations requires direct experimental assessment. 
Indeed, our direct measurements of Ki values in vitro 
and evaluation of effects in cells show a complex picture 
where different mutations, including replacements 
of the same residue, can have very profound effects 
on the efficacy of some inhibitors but not on others 
(Figures 6C and 6D). In the case of FGFR3 acquired 
gatekeeper mutation (V555M), this is illustrated by 
about 200-fold reduction in efficacy for JNJ42756493 
and an increase in efficacy for TKI258 (Figure 6C). 
Considering a good correlation between in vitro and in 
vivo effects of FGFR inhibitors in our previous study 
[37], these data are likely to be relevant for a cellular 
setting. Consistent with the in vitro data, we have 
observed loss of efficacy for PD173074 with the effect 
of TKI258 retained following introduction of FGFR3 
V555M mutation in a cell line originally responding to 
both drugs [37]. Because JNJ42756493 is also effective 
towards FGFR4 [20], these findings could be important 
when considering the use of JNJ42756493 as a first-line 
treatment; primary, activating mutations corresponding 
to gatekeeper replacements have been reported in 
rhabdomyosarcoma (FGFR4 V550L and V550E) and 
in breast cancer (FGFR4 V550M) [16, 38]. Another 
example that could inform the use of FGFR-selective 
inhibitors in the clinic is the effect of the hotspot 
N540K mutation on JNJ42756493 and AZD4547 that 
shows a larger impact on AZD4547 both in vitro and 
in cells (Figures 6C and 6D). Differential responses 
(response to TKI258 and AP24534 compared with 
reduced sensitivity to PD173074) due to the mutation 
corresponding to N540K, introduced in FGFR2 in the 
context of the JHUEM-2 cancer cell line, have been 
previously observed [46].
For aberrations where the FGFR KD retains the WT 
sequence (such as overexpression and a number of fusion 
proteins) the efficacy of both JNJ42756493 and AZD4547 
could be expected to be high, as we illustrate here using 
the WT protein in vitro and FGFR3TACC3-fusion in cells 
(Figures 6A and 6D). More broadly, previous assessments 
of efficacy of several FGFR-specific inhibitors in separate 
studies have shown a good response in cancers with gene 
amplification of the FGFR WT or fusion proteins; these 
studies were based on available panels of cancer cell lines 
and tumor xenografts [22, 42, 53–55]. However, there are 
only a few cancer cell lines harboring point mutations in 
the FGFR KD with just two mutations being represented, 
FGFR3 K650E and FGFR2 N550K. Due to various 
changes that co-occur with FGFR mutations in each of 
these cell lines, it was difficult to assess and compare 
their responses and obtain conclusive data. Therefore, 
our studies of drug efficacy performed in vitro and in 
stable cell lines, complement and expand these previous 
assessments and reveal differential, drug-specific impacts 
of different FGFR KD mutations.
MATERIALS AND METHODS
Generation of FGFR variants, protein 
purification and kinase assay
Proteins were expressed and purified as outlined 
in Bunney et al. [37]. Protein purity, integrity and 
phosphorylation status was assessed by native mass 
spectrometry and SDS-PAGE.
Auto-phosphorylation and substrate phosphorylation 
assays in vitro were performed using the ADP-Glo 
(Promega) methodology. Data for Ki values were analyzed 
using Graphpad Prism software where each data point was 
repeated in duplicate and the standard error of the mean 
presented as outlined in Bunney et al. [37]. A detailed 
description of the assay procedures can be found in the 
Supplementary Materials.
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Generation and analysis of stable NIH3T3 
cell lines
Cell culture, preparation of stable cell lines, 
protein analysis (including Western blotting and 
immunoprecipitation) and anchorage independent growth 
assays were essentially as previously described [21, 37, 
56] and are detailed in the Supplementary Materials.
Quantitation of Western blots was performed by Image 
Studio™ Lite and the standard deviation was calculated 
from two independent data sets. Residues of the full-
length FGFR3 IIIb were labeled consistently with the KD 
numbering (based on IIIc).
For the cell viability assay in the presence of 
FGFR inhibitors, NIH3T3 cells transfected with the 
stated FGFR3 variants were plated in 96-well plates, 
1000 cells per well. Twenty-four hours later the cells 
were treated with various concentrations of kinase 
inhibitor. Forty-eight hours later, fresh inhibitor was 
added and the cells incubated for 72 hours. Cell viability 
was measured through the addition of CellTiter-Glo 
(Promega) and luminenscence measured with a standard 
luminometer plate reader. Data were normalised and 
fitted to a log(inhibitor) vs. response curve (three 
parameters) with GraphPad Prism.
Crystallization, crystallography and NMR 
spectroscopy
FGFR1 crystals were grown by both, sitting and 
hanging drop methods and diffraction data collected at 
the Diamond Light source. Please refer to Supplementary 
Table S2 for X-ray data processing statistics. Phasing, 
refinement and structure validation are described in the 
Supplementary Materials.
The refined and validated structures of FGFR1R675G 
and FGFR1 bound to JNJ42756493 have been submitted 
to Protein Data Bank (PDB) and their PDB ID codes are 
5FLF and 5EW8 respectively.
For NMR spectroscopy, FGFR3 KD constructs, 
either the WT sequence or harboring R669G mutation, 
were uniformly labeled with 15N and purified as described 
in Bunney et al. [37]. 1H-15N TROSY-HSQC NMR spectra 
were acquired at 25°C.
Computational methods
We obtained pan-cancer mutation frequencies 
for each FGFR3c amino acid by collating somatic 
missense mutations from COSMIC v71 and other 
cancer genome sources, alongside germ line Skeletal 
Dysplasia mutations from UniProt. Mutants were 
assessed for predicted structural effects, pathogenicity 
and protein stability. For full computational methods see 
Supplementary Materials.
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